Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- <scp>d</scp> -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis

Abstract

Our strategy limits ischemic damages and extends the therapeutic window of tPA-driven thrombolysis. Thus, the prospect of this immunotherapy is an extension of the range of treatable patients.